Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-β1 during haemodialysis: A cross-over study

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1690-1696

  Naumnik, Beata ^a   Borawski, Jacek ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Enoxaparin; Haemodialysis; Transforming growth factor 1; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; ERYTHROPOIETIN; HEPARIN; PLATELET DERIVED GROWTH FACTOR AB; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMYLOIDOSIS; ANTICOAGULATION; ARTICLE; BOLUS INJECTION; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION;

AGED; ANTICOAGULANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; RENAL DIALYSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34447571968     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm082     Document Type: Article

References (22)

1. Junker U, Haufe CC, Nuske K et al. Elevated plasma TGF-β1 in renal disease: Cause or consequence? Cytokine 2000; 12: 1084-1091
2. Grainger DJ. Transforming growth factor β and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404
3. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-β in blood: A complex problem. Cytokine Growth Factor Rev 2000; 11: 133-145
4. McCaffrey TA, Falcone DJ, Brayton CF et al. Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2macroglobulin inactive complex. J Cell Biol 1989; 109: 441-448
5. Blobe GC, Schiemann P, Lodish HF. Role of transforming growth factor beta in human diseases. N Engl J Med 2000; 342: 1350-1358
6. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-β is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-β1. J Cell Physiol 1992; 152: 430-440
7. McCaffrey TA, Falcone DJ, Vicente D et al. Protection of transforming growth factor-beta1 activity by heparin and fucoidan. J Cell Physiol 1994; 159: 51-59
8. Rider CC. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans 2006; 34: 458-60
9. Ceol M, Vianello D, Schleicher E et al. Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol 2003; 16: 210-218
10. Hetzel GR, Sucker C. The heparins: All a nephrologists should know. Nephrol Dial Transplant 2005; 20: 2036-2042
11. Stefoni S, Cianciolo G, Donati G et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324-335
12. Füth R, Herder C, Förster S et al. Evaluation of diagnostic relevance of mRNA levels in peripheral blood: Predictive value for mortality in hemodialysis patients. Cytokine 2004; 27: 166-172
13. Naumnik B, Borawski J, Myśliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: A prospective study. Nephrol Dial Transplant 2003; 18: 1376-1382
14. Vignoli A, Marchetti M, Balducci D et al. Differential effect of low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006; 91: 207-214
15. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999; 14: 2698-2703
16. Wakefield LM, Letterio JJ, Chen T et al. Transforming growth factor-beta 1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129-136
17. Stefoni S, Cianciolo, G, Donati G et al. Standard heparin versus low-molecular-weight heparin. Nephron 2002, 92: 589-600
18. Jiang X, Kanai H, Shigehara T et al. Metabolism of transforming growth factor-beta in patients receiving hemodialysis especially those with renal osteodystrophy. Ren Fail 1998; 20: 135-145
19. Fujisawa M, Haramaki R, Miyazaki H et al. Role of lipoprotein (a) and TGF-β1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 2000; 11: 1889-1895
20. Cianciolo G, Stefoni S, Donati G et al. Intra-and postdialytic platelet activation and PDGF-AB release: Cellulose diacetate vs polysulfone membranes. Nephrol Dial Transplant 2001; 16: 1222-1229
21. Sagedal S, Hartmann A, Sundstrom K et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001; 16: 987-993
22. Matsuo K, Ikizler TA, Hoover RL et al. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int 2000; 57: 697-708